- Home
- EPC vs TRML Comparison
EPC vs TRML Comparison
Compare EPC & TRML Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EPC
- TRML
- Stock Information
- Founded
- EPC 1999
- TRML 2021
- Country
- EPC United States
- TRML United States
- Employees
- EPC N/A
- TRML N/A
- Industry
- EPC Package Goods/Cosmetics
- TRML Biotechnology: Pharmaceutical Preparations
- Sector
- EPC Consumer Discretionary
- TRML Health Care
- Exchange
- EPC Nasdaq
- TRML Nasdaq
- Market Cap
- EPC 1.4B
- TRML 1.2B
- IPO Year
- EPC 2000
- TRML N/A
- Fundamental
- Price
- EPC $19.72
- TRML $47.98
- Analyst Decision
- EPC Buy
- TRML Hold
- Analyst Count
- EPC 6
- TRML 12
- Target Price
- EPC $26.33
- TRML $47.04
- AVG Volume (30 Days)
- EPC 542.6K
- TRML 646.9K
- Earning Date
- EPC 11-13-2025
- TRML 11-13-2025
- Dividend Yield
- EPC 3.05%
- TRML N/A
- EPS Growth
- EPC N/A
- TRML N/A
- EPS
- EPC 1.34
- TRML N/A
- Revenue
- EPC $2,203,900,000.00
- TRML N/A
- Revenue This Year
- EPC N/A
- TRML N/A
- Revenue Next Year
- EPC $2.18
- TRML N/A
- P/E Ratio
- EPC $14.69
- TRML N/A
- Revenue Growth
- EPC N/A
- TRML N/A
- 52 Week Low
- EPC $19.13
- TRML $11.56
- 52 Week High
- EPC $38.45
- TRML $48.27
- Technical
- Relative Strength Index (RSI)
- EPC 39.17
- TRML 90.41
- Support Level
- EPC $19.50
- TRML $47.88
- Resistance Level
- EPC $20.30
- TRML $48.00
- Average True Range (ATR)
- EPC 0.50
- TRML 0.05
- MACD
- EPC 0.08
- TRML -0.81
- Stochastic Oscillator
- EPC 23.17
- TRML 89.19
About EPC Edgewell Personal Care Company
Edgewell Personal Care Co is a personal-care company. The operating segments of the company include Wet Shave, Sun and Skin Care and Feminine Care. Some of the brands offered by the company include Edge, Skintimate, Personna, Schick, Carefree, Playtex, Banana Boat and Hawaiian Tropic. It derives a majority of its revenue from the United States.
About TRML Tourmaline Bio Inc.
Tourmaline Bio Inc is a late-stage clinical biotechnology company driven by its mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune diseases. Its initial product candidate is TOUR006, a fully human monoclonal antibody that selectively binds to interleukin-6 (IL-6), a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The anti-IL-6 and anti-IL-6 receptor (IL-6R) antibody class (IL-6 class) has over two decades of clinical and commercial experience treating over a million patients with a variety of autoimmune and inflammatory diseases.